TEM is trading down -8.99% to about $76.04 during regular market hours, erasing Monday's +9.03% surge that followed FDA 510(k) clearance for its ECG-MR AI tool. The decline is driven by continued large-scale insider selling: CEO Eric Lefkofsky has sold over 1 million Class A shares since mid-September, at prices between roughly $76 and $81.

Different ends of the spectrum: BEAT is a pre-revenue, micro-cap medical device developer, while MDT is a diversified, dividend-paying global healthcare technology leader. Recent catalysts diverge: BEAT's recent momentum has been driven by an FDA (U.S. Food and Drug Administration) Breakthrough Device Designation, whereas MDT's story centers on durable organic growth and raised guidance.

BEAT jumped roughly +60% to about $0.69 during Monday's regular session, up from Friday's $0.43 close. Primary catalyst: the FDA granted Breakthrough Device Designation for HeartBeam's at-home 3D ECG heart attack assessment system.

The $3.50 central target is the arithmetic mean of five verified analyst price targets, which range widely from $2.00 to $5.00. With shares near $0.43, reaching $3.50 would require a gain of roughly 714%, a very large move.

BEAT is up +69.77% during Monday's regular session, trading around $0.73 versus Friday's roughly $0.43 close, after spiking as much as ~90% intraday. The primary catalyst: the FDA granted Breakthrough Device Designation for HeartBeam's at-home heart attack assessment tool built on its 3D ECG platform.

Strategic pivot underway: HeartBeam is shifting from direct medical-device sales toward licensing its proprietary 3D ECG (electrocardiogram) signal platform to established distribution partners, a move aimed at faster global adoption with a leaner cost structure. Major clinical catalyst: Expanding beyond arrhythmia assessment into heart attack detection represents the company's largest addressable-market opportunity and a central focus of its near-term evidence-building efforts.

Two different instruments, one company: ONMD is OneMedNet Corporation's common stock, while ONMDW is a derivative warrant tied to the same underlying business. Distinct risk profiles: The common stock reflects the operating company directly, whereas the warrant adds leverage, time-decay, and exercise-price sensitivity on top of business fundamentals.

HNGE shares have climbed roughly 9% over the trailing 30 days, holding near 52-week highs after a powerful 2026 run. Second-quarter 2026 revenue rose 53% year over year to $213 million, while operating margin expanded to 29% from 19%.

Schrödinger (SDGR) closed near $29.45 after a powerful rally that took shares roughly 140% higher over six months and pushed the stock to fresh 52-week highs. The $40 stock price target represents a meaningful move of roughly 35% above recent levels and sits well above the stock's current 52-week high near $31.59.

Schrödinger (SDGR) shares rose roughly 71% over the 30 days ending September 17, 2026, climbing from about $17.67 to $30.24 and reaching a new 52-week high. The rally reflects growing investor enthusiasm for AI-driven drug discovery, the launch of the Bunsen AI co-scientist, and the formation of Tectora Therapeutics.

TEM is up +10.36% during regular trading hours, trading near $77.22 versus a $69.97 prior close. Primary catalyst: Piper Sandler upgraded the stock to Overweight from Neutral and raised its price target to $76 from $56.

Tempus AI (TEM) climbed roughly 35.5% over the trailing 30 days, from about $51.64 to $69.97 on a closing basis. The advance was amplified by a technical short squeeze tied to positive third-party precision-medicine news and an expanded AI collaboration with Merck.

The central question is whether SOPHiA GENETICS SA (SOPH) can climb to a $10 stock price target, roughly 25% above recent trading levels. Bullish drivers include accelerating revenue growth, raised full-year guidance, expanding U.S. traction, and high-profile companion-diagnostics partnerships.

TEM shares surged +10.67% during regular trading, climbing from a prior close of $62.21 to about $68.85. The rally followed Piper Sandler's upgrade to Overweight with a raised $76 price target, citing the Personalis acquisition, positive INTerpath-001 trial data, and FDA clearance of the xT CDx test.

Selected price target: $80 per share, a level cited by multiple Wall Street firms including Cantor Fitzgerald, BTIG, Canaccord Genuity, and Raymond James. Strongest bullish factors: accelerating revenue growth, a first quarter of GAAP profitability, FDA approval for a key diagnostic, and the pending Personalis acquisition.

Omada Health shares fell roughly -7.86% during regular trading, dropping from a $21.50 prior close to about $19.81. The decline follows the company's inaugural Investor Day on Sept. 10, where new long-term targets (80% non-GAAP gross margin, 30% adjusted EBITDA margin) failed to satisfy investors, triggering a "sell-the-news" reaction.

DOCS closed up +2.15% (+$0.52) to $24.71 in Wednesday's regular session, rebounding from the prior close of $24.19. The gain was a technical rebound and bargain-buying after shares fell roughly -7% earlier in the week following a downgrade to Hold.

PHR is trading down -8.61% to $10.83, after closing the prior session at $11.85, with the decline gapping down in premarket and continuing during regular hours. The primary catalyst was a Q2 FY2027 earnings miss: adjusted EPS of $0.03 fell short of the $0.09 consensus, overshadowing revenue of $129.5M that slightly beat estimates.

Tempus AI shares rose roughly 70% over the last 30 days, climbing from about $41.55 on July 29, 2026, to $70.69 on August 27, 2026. The sharpest move came after a Phase 3 melanoma win from Merck and Moderna validated Tempus's pending $1.5 billion acquisition of Personalis.

VEEV surged +19.63% to roughly $292.98 during regular trading, building on a strong post-earnings reaction. The rally followed fiscal Q2 results: revenue rose +17.6% year over year to $927.96 million, above the ~$905 million consensus.